Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

Summary

The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activity.

Timeline

Start

2022-08-09

Primary completion

2025-02-12

Completion

2025-02-12

Outcome

Outcome not reported

Stopped: “Sponsor decided to terminate the study”

Drugs

Indications